Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | HBB | P68871 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16810688 | 0.85 | SLC6A3 (0.41) | RAB9AALDH1A1POLBUSP2HPGD | |
| SCHEMBL19031436 | 0.81 | RAB9A (0.43) | RAB9AALDH1A1POLBUSP2HPGD | |
| SCHEMBL2256127 | 0.79 | — | — | |
| Ammonia Solution, Strong SCHEMBL27615021 | 0.77 | SLC6A3 (0.46) | RAB9AALDH1A1POLBNPC1SLC6A3 | |
| Hydrochloric Acid SCHEMBL10988638 | 0.77 | SLC6A3 (0.46) | RAB9AALDH1A1POLBMAPTNPC1 | |
| SCHEMBL736037 | 0.76 | — | — | |
| SCHEMBL16373704 | 0.74 | SLC6A3 (0.36) | RAB9AALDH1A1POLBHPGDMAPT | |
| SCHEMBL14920499 | 0.74 | — | — | |
| SCHEMBL25226302 | 0.74 | — | — | |
| SCHEMBL11926805 | 0.74 | SLC6A3 (0.49) | RAB9APOLBNPC1SLC6A3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1527070-B1 | AZOLE METHYLIDENE CYANIDE DERIVATIVES AND THEIR USE AS PROTEIN KINASE MODULATORS | MERCK SERONO SA (CH) | 2013-01-09 | — | — | EP | disclosed |
| EP-1527070-B1 | AZOLE METHYLIDENE CYANIDE DERIVATIVES AND THEIR USE AS PROTEIN KINASE MODULATORS | MERCK SERONO SA (CH) | 2013-01-09 | — | — | EP | disclosed |
| US-7465736-B2 | Azole methylidene cyanide derivatives and their use as protein kinase modulators | LABORATOIRES SERONO S.A. (CH) | 2008-12-16 | — | — | US | disclosed |
| US-7465736-B2 | Azole methylidene cyanide derivatives and their use as protein kinase modulators | LABORATOIRES SERONO S.A. (CH) | 2008-12-16 | — | — | US | disclosed |
| US-7465736-B2 | Azole methylidene cyanide derivatives and their use as protein kinase modulators | LABORATOIRES SERONO S.A. (CH) | 2008-12-16 | — | — | US | disclosed |
| US-20070123530-A1 | Azole methylidene cyanide derivatives and their use as protein kinase modulators | MERCK SERONO SA (CH) | 2007-05-31 | — | — | US | disclosed |
| US-20070123530-A1 | Azole methylidene cyanide derivatives and their use as protein kinase modulators | MERCK SERONO SA (CH) | 2007-05-31 | — | — | US | disclosed |
| US-20070123530-A1 | Azole methylidene cyanide derivatives and their use as protein kinase modulators | MERCK SERONO SA (CH) | 2007-05-31 | — | — | US | disclosed |
| EP-1527070-A1 | AZOLE METHYLIDENE CYANIDE DERIVATIVES AND THEIR USE AS PROTEIN KINASE MODULATORS | Applied Research Systems ARS Holding N.V. (AN) | 2005-05-04 | — | — | EP | disclosed |
| WO-2003106455-A1 | AZOLE METHYLIDENE CYANIDE DERIVATIVES AND THEIR USE AS PROTEIN KINASE MODULATORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003106455-A1 | AZOLE METHYLIDENE CYANIDE DERIVATIVES AND THEIR USE AS PROTEIN KINASE MODULATORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123530-A1 | Azole methylidene cyanide derivatives and their use as protein kinase modulators | PRKACA, CSNK1A1, PRKACG | RAB9A 3831/4885ALDH1A1 3474/4885POLB 3560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.